NASDAQ: AUTLAutolus Therapeutics PLC Stock
$1.79-0.04 (-2.19%)
Updated Oct 6, 2026
AUTL Price
$1.79
Fair Value Price
N/A
Market Cap
$476.43M
52 Week Low
$1.18
52 Week High
$2.58
P/E
-1.69x
P/B
6.37x
P/S
3.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$117.39M
Earnings
-$280.16M
Gross Margin
15.7%
Operating Margin
-202.47%
Profit Margin
-238.7%
Debt to Equity
5.59
Operating Cash Flow
-$226M
Beta
1.15
Next Earnings
Nov 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AUTL Overview
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AUTL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AUTL
Ranked#97 of 459
Ranked#97 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.50 | A | |
| $7.55 | A | |
| $10.35 | A |
Be the first to know about important AUTL news, forecast changes, insider trades & much more!
AUTL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AUTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AUTL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AUTL is poor value based on its book value relative to its share price (6.37x), compared to the US Biotechnology industry average (4.99x)
P/B vs Industry Valuation
AUTL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AUTL due diligence checks available for Premium users.
Valuation
AUTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.69x
Industry
12.56x
Market
51.93x
AUTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.37x
Industry
4.99x
AUTL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AUTL's financial health
Profit margin
Revenue
$45.7M
Net Income
-$39.1M
Profit Margin
-85.6%
AUTL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AUTL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$493.2M
Liabilities
$418.4M
Debt to equity
5.59
AUTL's short-term assets ($336.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUTL's long-term liabilities ($349.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUTL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AUTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.1M
Investing
$67.9M
Financing
-$2.1M
AUTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AUTL vs Biotech Stocks
Autolus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.